Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Ascending Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of APG-5918 in Healthy Volunteers and Patients With Anemia.

NCT05773586 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT05773586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05773586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Ascending Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of APG-5918 in Healthy Volunteers and Patients With Anemia.
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 13, 2023
Completion date
July 15, 2028
Enrollment
105 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anemia